Physician profile
Travis Kanaly
NPI 1750594099
$2,283.45
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,018 · 2020: $137 · 2021: $48.55 · 2022: $51.54 · 2023: $27.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $27.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $27.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $242.11 | 2019-2020 | |
| Mdd US Operations, LLC | $217.06 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $188.74 | 2019 | |
| Supernus Pharmaceuticals, INC. | $160.82 | 2019 | |
| Ucb, INC. | $128.66 | 2019 | |
| Genzyme Corporation | $117.91 | 2019 | |
| Livanova USA, INC. | $116.35 | 2019 | |
| Abbvie INC. | $115.21 | 2021-2023 | |
| Lundbeck LLC | $99.68 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $76.78 | 2019 | |
| Genentech USA, INC. | $73.94 | 2019 | |
| Vertical Pharmaceuticals, LLC | $71.72 | 2019 | |
| Amgen INC. | $68.35 | 2019 | |
| Biogen, INC. | $58.37 | 2019 | |
| Lilly USA, LLC | $56.71 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $55.78 | 2019 | |
| Acorda Therapeutics, INC | $48.74 | 2019 | |
| Eisai INC. | $47.87 | 2019 | |
| Allergan, INC. | $46.68 | 2019 | |
| Avanir Pharmaceuticals, INC. | $45.49 | 2019 | |
| Promius Pharma LLC | $44.52 | 2019 | |
| Upsher-Smith Laboratories LLC | $38.02 | 2019 | |
| Alexion Pharmaceuticals, INC. | $35.24 | 2019 | |
| Amneal Pharmaceuticals LLC | $27.30 | 2019 | |
| Neurocrine Biosciences, INC. | $25.44 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $23.28 | 2019 | |
| Adamas Pharmaceuticals, INC. | $18.72 | 2019 | |
| Zogenix INC. | $12.60 | 2021 | |
| Acadia Pharmaceuticals INC | $11.75 | 2019 | |
| Travere Therapeutics, INC. | $9.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Kanaly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.